YOLFTbeta
60

Shaanxi Kanghui Pharm Co Ltd

603139 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

28.50CNY-0.65 (-2.23%)

Price History

Full chart

Market Stats

Previous Close29.15
Open29.42
Day Range28.46 – 29.68
52-Week Range19.91 – 46.92
Volume1.49M
Market Cap3.64B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.85
Dividend Yield0.00%
Beta0.58
50-Day Avg35.78
200-Day Avg31.91

About

Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biological products, blood products, pharmaceuticals, and traditional Chinese medicine. The company also provides products for the treatment of dermatological, respiratory, gynecological, and orthopedic diseases. Shaanxi Kanghui Pharmaceutical Co., Ltd. was founded in 1999 and is based in Xianyang, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Binze Zou
  • Employees804
  • HeadquartersNo. 36 Yanzhi Road, Xianyang, China, 712000, China
  • Websitehttps://www.sxkh.com

Leadership

  • Mr. Binze ZouAccounting Supervisor · b. 1987
  • Ms. Juan DongBoard Secretary · b. 1981
  • Ms. Wang JingGeneral Manager · b. 1984

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue276.82M328.06M375.73M379.79M381.85M367.06M375.62M431.42M414.07M442.76M491.51M672.96M561.63M471.29M
Growth (%)-+18.51%+14.53%+1.08%+0.54%-3.87%+2.33%+14.86%-4.02%+6.93%+11.01%+36.92%-16.54%-16.09%
Cost of Revenue119.76M141.81M161.77M163.57M164.49M157.65M187.00M228.46M221.41M241.87M303.02M489.21M405.90M351.80M
Gross Profit157.06M186.26M213.96M216.22M217.35M209.41M188.62M202.97M192.66M200.88M188.49M183.75M155.73M119.48M
Gross Margin56.74%56.77%56.94%56.93%56.92%57.05%50.22%47.05%46.53%45.37%38.35%27.30%27.73%25.35%
Operating Expense105.99M121.44M140.40M142.94M142.59M135.64M123.56M146.29M149.48M162.15M264.18M245.55M278.72M204.25M
Operating Income51.07M64.82M73.56M73.28M74.76M73.77M65.06M56.67M43.18M38.74M-75.69M-61.80M-122.99M-84.77M
Operating Margin18.45%19.76%19.58%19.29%19.58%20.10%17.32%13.14%10.43%8.75%-15.40%-9.18%-21.90%-17.99%
EBITDA50.35M70.24M85.09M84.57M88.68M84.67M79.49M68.03M57.01M61.34M-43.94M2.35M-27.66M-243.06M
EBITDA Margin18.19%21.41%22.65%22.27%23.22%23.07%21.16%15.77%13.77%13.85%-8.94%0.35%-4.92%-51.57%
Net Income40.40M55.82M62.74M62.21M65.23M63.02M55.63M42.76M34.11M36.48M-63.06M-26.16M-89.63M-333.45M
Net Income Margin14.59%17.02%16.70%16.38%17.08%17.17%14.81%9.91%8.24%8.24%-12.83%-3.89%-15.96%-70.75%
R&D11.99M14.13M14.63M14.86M15.05M6.71M6.51M8.22M10.36M10.15M12.35M10.98M10.25M12.15M
R&D as % of Total Revenue4.33%4.31%3.89%3.91%3.94%1.83%1.73%1.90%2.50%2.29%2.51%1.63%1.82%2.58%
Interest Expense01.36M2.47M2.12M2.45M1.42M441.47K260.07K1.51M6.38M13.46M23.46M35.10M34.34M
Interest Expense % of Total Revenue0.00%0.42%0.66%0.56%0.64%0.39%0.12%0.06%0.36%1.44%2.74%3.49%6.25%7.29%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets315.74M450.00M507.65M578.40M654.97M1.03B1.11B1.13B1.31B1.86B1.82B2.05B1.89B1.81B
Total Liabilities105.31M117.37M112.27M120.82M132.16M119.70M130.88M113.85M238.27M745.20M795.75M1.03B980.94M1.25B
Total Equity210.43M332.63M395.37M457.58M522.81M910.82M946.48M978.24M1.01B1.05B973.73M949.23M857.32M524.92M
Cash45.37M47.00M54.91M66.95M161.56M232.91M220.19M295.70M194.91M203.96M226.27M163.75M97.60M107.71M
Total Debt45.00M36.30M35.40M34.60M34.00M6.95M6.89M22.68M66.74M484.54M531.70M484.44M521.12M-
Net Debt-369.72K-10.70M-19.51M-32.35M-127.56M-225.96M-213.30M-273.02M-128.17M280.58M305.42M320.68M423.52M383.21M

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow16.12M39.35M22.72M28.50M71.72M43.60M62.64M107.53M93.72M7.42M50.43M-72.13M37.29M-16.72M
Investing Cash Flow-9.88M-92.02M-11.76M-12.04M25.79M-260.68M-47.70M-63.24M-197.86M-378.98M-43.40M-45.97M-16.52M-
Financing Cash Flow-3.56M54.29M-3.05M-4.42M-2.91M288.44M-27.66M1.23M23.33M378.31M7.59M54.65M-65.99M-
Capital Expenditure11.17M50.77M19.30M12.60M4.81M3.59M5.58M81.45M262.89M290.30M138.13M72.38M46.66M15.53M
Free Cash Flow4.95M-11.42M3.42M15.90M66.91M40.01M57.05M26.08M-169.16M-282.88M-87.70M-144.52M-9.37M-32.25M
Dividends Paid3.22M2.91M2.47M2.12M1.76M4.33M21.18M11.29M8.59M6.99M7.39M30.73M28.93M27.86M
FCF to OCF30.73%-29.01%15.06%55.80%93.29%91.76%91.09%24.25%-180.49%-3813.08%-173.89%200.34%-25.11%192.91%
Dividend Paid to FCF64.91%-25.47%72.13%13.33%2.62%10.83%37.12%43.28%-5.08%-2.47%-8.43%-21.26%-308.85%-86.36%

Earnings

Report DateAug 22, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 19, 2020Oct 28, 2020Dec 31, 2020Apr 23, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate------------------------
EPS Actual0.110.160.270.100.130.100.230.100.090.130.100.070.090.130.050.090.060.060.150.090.050.02-0.790.08
Surprise------------------------
TimingPre-market-----------------------

Key Statistics & Ratios

Market Cap3.64B
Enterprise Value4.38B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.48
Price / Book7.28
EPS-2.85
Book Value5.36
Revenue (TTM)429.09M
Gross Profit (TTM)96.39M
EBITDA-54.30M
Profit Margin-66.22%
Operating Margin-1.06%
Return on Equity-37.43%
Return on Assets-3.90%
Shares Outstanding106.45M
Shares Float47.18M
Beta0.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20221×
0.07Jun 29, 2022
20211×
0.07Jun 24, 2021
20201×
0.09Jul 13, 2020
20191×
0.11Jul 24, 2019
20181×
0.20Jun 22, 2018